Effect of daclizumab HYP treatment in highly active relapsing-remitting multiple sclerosis: Results from the SELECT study

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2012
This article has no abstract
Epistemonikos ID: fc5a5f10d47ec76d098682e8f8f1f857d6475bd8
First added on: Apr 30, 2026